MX2023004170A - Compuestos y oligonucleótidos derivados de n-acetilgalactosamina (galnac). - Google Patents

Compuestos y oligonucleótidos derivados de n-acetilgalactosamina (galnac).

Info

Publication number
MX2023004170A
MX2023004170A MX2023004170A MX2023004170A MX2023004170A MX 2023004170 A MX2023004170 A MX 2023004170A MX 2023004170 A MX2023004170 A MX 2023004170A MX 2023004170 A MX2023004170 A MX 2023004170A MX 2023004170 A MX2023004170 A MX 2023004170A
Authority
MX
Mexico
Prior art keywords
galnac
acetylgalactosamine
oligonucleotides
derived compounds
symptoms
Prior art date
Application number
MX2023004170A
Other languages
English (en)
Inventor
Zhen Li
Chandramouli Chiruta
Rui Zhu
Mehdi Michel Djamel Numa
Bo Cheng
Chase Robert Olsson
Indrasena Reddy Kummetha
Original Assignee
Adarx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adarx Pharmaceuticals Inc filed Critical Adarx Pharmaceuticals Inc
Publication of MX2023004170A publication Critical patent/MX2023004170A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

En el presente documento se proporcionan compuestos derivados de N-acetilgalactosamina (GalNAc), oligonucleótidos modificados y métodos para modular la función de proteínas y tratar enfermedades, trastornos y síntomas en un sujeto.
MX2023004170A 2020-10-09 2021-10-08 Compuestos y oligonucleótidos derivados de n-acetilgalactosamina (galnac). MX2023004170A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063089936P 2020-10-09 2020-10-09
US202063113801P 2020-11-13 2020-11-13
US202063131317P 2020-12-29 2020-12-29
US202163141300P 2021-01-25 2021-01-25
US202163146276P 2021-02-05 2021-02-05
US202163251580P 2021-10-01 2021-10-01
PCT/US2021/054318 WO2022076922A1 (en) 2020-10-09 2021-10-08 N-ACETYLGALACTOSAMINE(GAlNAc)-DERIVED COMPOUNDS AND OLIGONUCLEOTIDES

Publications (1)

Publication Number Publication Date
MX2023004170A true MX2023004170A (es) 2023-06-27

Family

ID=81126164

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004170A MX2023004170A (es) 2020-10-09 2021-10-08 Compuestos y oligonucleótidos derivados de n-acetilgalactosamina (galnac).

Country Status (9)

Country Link
US (1) US20240083934A1 (es)
EP (1) EP4225322A1 (es)
JP (1) JP2023546369A (es)
KR (1) KR20230113285A (es)
AU (1) AU2021359017A1 (es)
CA (1) CA3198406A1 (es)
IL (1) IL302000A (es)
MX (1) MX2023004170A (es)
WO (1) WO2022076922A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117836307A (zh) * 2021-06-18 2024-04-05 弘景生物科技有限公司 功能化的n-乙酰基半乳糖胺核苷
US11692001B2 (en) 2021-08-30 2023-07-04 Hongene Biotech Corporation Functionalized n-acetylgalactosamine analogs
WO2023220737A2 (en) * 2022-05-13 2023-11-16 Adarx Pharmaceuticals, Inc. Oligonucleotides having a synthetic backbone and synthesis thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US6852485B1 (en) * 2002-01-22 2005-02-08 California State University Fullerton Foundation Method for identifying a compound for the treatment of microorganism infections by inhibiting energy storage and utilization in pathogens
EP3238738B1 (en) * 2008-11-10 2020-09-23 Arbutus Biopharma Corporation Novel lipids and compositions for the delivery of therapeutics

Also Published As

Publication number Publication date
AU2021359017A1 (en) 2023-05-25
US20240083934A1 (en) 2024-03-14
KR20230113285A (ko) 2023-07-28
EP4225322A1 (en) 2023-08-16
IL302000A (en) 2023-06-01
JP2023546369A (ja) 2023-11-02
CA3198406A1 (en) 2022-04-14
WO2022076922A1 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
MX2023004170A (es) Compuestos y oligonucleótidos derivados de n-acetilgalactosamina (galnac).
MX2022010425A (es) Metodos de tratamiento de enfermedades asociadas a los receptores de estrogenos.
MX2020009773A (es) Terapia de combinacion.
BR112012004546A8 (pt) Terapêutica por proteínas ligantes dll4-ligantes
WO2017177179A9 (en) Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
WO2019166412A9 (en) Modulation of pla2-g1b in therapy
NZ588435A (en) Use of a polypeptide with an angiotensin-converting enzyme 2 (ACE2) activity for treating tumours (with the exception of lung cancer)
MX2022009596A (es) Anticuerpos anti-ror1 y composiciones.
MX2023004156A (es) Terapia combinada para el tratamiento del cancer.
MX2019011717A (es) Composiciones y metodos para focalizar y matar celulas madre positivas a cancer alfa-v beta-3 y tratar cancer resistentes a farmacos.
MX2021012335A (es) Anticuerpos humanos que se unen a ret y metodos de uso de los mismos.
WO2022081718A8 (en) Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
BR112021022363A2 (pt) Composições e métodos para fabricação de células t
MX2021014905A (es) Células seguras e invisibles para el sistema inmunitario.
MX2023003984A (es) Metodos y composiciones para terapia genica con placofilina-2.
MX2022011550A (es) Composiciones y métodos para inhibir la expresión de angptl3.
WO2023018722A3 (en) Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8
MX2022005345A (es) Terapia de combinación para el tratamiento de cáncer cerebral.
AU2021386366A9 (en) Adoptive cell therapy for treatment of cancer associated with loss of heterozygosity
MX2021003262A (es) Metodos de tratamiento.
CL2023000437A1 (es) Metodos y composiciones de fabricacion de celulas t
MX2021003265A (es) Metodos de tratamiento.
MX2023005591A (es) Metodos de tratamiento de enfermedades y trastornos.
WO2021229507A3 (en) Methods, therapies and uses for treating cancer
MX2023001881A (es) Tratamiento con ribitol.